Genentech: Home

News & Features

		Topline Phase III Study Results of Trastuzumab Emtansine (T-DM1) Announced On March 29, 2012, Genentech announced the Phase III EMILIA study of trastuzumab emtansine met its endpoint. Read more



		FDA Grants Pertuzumab Priority Review On February 7, 2012, Genentech announced the FDA accepted the company’s Biologics License Application for pertuzumab and granted Priority Review. Read more

SCIENTIFIC LEADERSHIP Genentech, the Banner Alzheimer's Institute and the National Institutes of Health partner for first-ever study of cognitively healthy individuals who are likely to develop Alzheimers disease due to their genetic history.



DEVELOPMENT PIPELINE Our research and development activities are focused on applying excellent science to discover and develop potential new medicines. See our pipeline